<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent studies using middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in the rat have suggested a role of neuropeptide Y in ischemic pathophysiology </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we investigated the effects of an i.c.v. injection of a neuropeptide Y-Y2 receptor <z:chebi fb="4" ids="48705">agonist</z:chebi>, neuropeptide Y 3-36, a Y1 receptor <z:chebi fb="4" ids="48705">agonist</z:chebi>, [Leu(31),Pro(34)]-neuropeptide Y, or a Y1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, BIBP3226, on <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and hemodynamic parameters following middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Adult male Sprague-Dawley rats were subjected to transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 2 h </plain></SENT>
<SENT sid="3" pm="."><plain>A single i.c.v. injection of neuropeptide Y 3-36 (15 microg/kg), [Leu(31),Pro(34)]-neuropeptide Y (30 microg/kg), or BIBP3226 (5, 15, or 45 microg/kg) was given at 30 min of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Blood pressure, heart rate, and regional cerebral perfusion were monitored during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain>The rats were decapitated after 70 h of reperfusion, and their brains were cut into 2-mm-thick coronal slices before reaction with a 2% solution of 2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> to reveal the <z:mpath ids='MPATH_124'>infarct</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>When compared with an <z:mpath ids='MPATH_124'>infarct</z:mpath> volume of 17.4+/-4.4% of the ipsilateral hemisphere following injection of neuropeptide Y 3-36, administration of the Y1 receptor analogs significantly modified the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (ordinary one-way analysis of variance (ANOVA), P&lt;0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain>[Leu(31),Pro(34)]-neuropeptide Y increased the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume to 32.0+/-4.1% (Student-Newman-Keuls post-test, P&lt;0.01), whereas BIBP3226 at 15 microg/kg decreased the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume to 6.5+/-1.0% (post-test P&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Although there was no major difference in the hemodynamic parameters among the groups, injection of [Leu(31),Pro(34)]-neuropeptide Y tended to further reduce cerebral perfusion during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, while injection of BIBP3226 at 15 microg/kg appeared to have the opposite effect </plain></SENT>
<SENT sid="9" pm="."><plain>In addition to <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi>, <z:chebi fb="0" ids="39124">calcium ion</z:chebi> and nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi>, activation of the neuropeptide Y-Y1 receptors may mediate cerebral damage during focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Conversely, inhibiting the Y1 receptors may protect the brain against ischemic injury </plain></SENT>
<SENT sid="11" pm="."><plain>Further studies are warranted to confirm the neuroprotective potential of neuropeptide Y-Y1 receptor inhibition </plain></SENT>
</text></document>